NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, H.P. Bagshaw, Michael J. Baine, Kathryn E. Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Andrew J. Gunn, Naomi B. Haas, Michael P. Johnson, Payal Kapur, Jennifer King, Christos E. Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon J. Manley, M. Dror Michaelson, Amir Mortazavi, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey A. Sosman, Randy F. Sweis, Matthew R. Zibelman, Ryan Schonfeld, MaryElizabeth Stein, Lisa A. Gurski
Abstract
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic therapy options for patients with advanced RCC and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Kidney Cancer.